Search research articles
Contact Us
Filters
Showing results (61-70 of 71) with videos related to
Page
of 8
Sort By:
ERJ Open Research
|
April 13, 2022
Prospective longitudinal evaluation of hospitalised COVID-19 survivors 3 and 12 months after discharge
Natalie Lorent, Yannick Vande Weygaerde, Eveline Claeys, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
April 2, 2026
Effects of Elexacaftor/Tezacaftor/Ivacaftor on cough frequency, physical activity patterns, and sleep quality in adolescents and adults with cystic fibrosis
Eva Van Braeckel, Andrew T Braun, Nicholas J Simmonds, et al.
Respiratory Research
|
August 9, 2022
Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
Elisabeth De Leeuw, Karel F A Van Damme, Jozefien Declercq, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
March 20, 2026
Determinants of early Elexacaftor-Tezacaftor-Ivacaftor use in adults with cystic fibrosis and preserved lung function: insights from a European multicenter survey
Andrea Gramegna, Carlo Magnoni, Chiara Premuda, et al.
Cell Reports. Medicine
|
December 2, 2022
Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment
Cedric Bosteels, Karel F A Van Damme, Elisabeth De Leeuw, et al.
ERJ Open Research
|
July 14, 2026
The association between chronic rhinosinusitis, bronchiectasis and type 2 inflammation: an EMBARC registry analysis
Michal Shteinberg, Charles S Haworth, Jennifer Pollock, et al.
The Journal of Allergy and Clinical Immunology
|
February 24, 2024
Bronchiectasis and asthma: Data from the European Bronchiectasis Registry (EMBARC)
Eva Polverino, Katerina Dimakou, Letizia Traversi, et al.
Thorax
|
March 23, 2025
Use of inhaled corticosteroids in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)
Jennifer Pollock, Eva Polverino, Raja Dhar, et al.
The European Respiratory Journal
|
April 12, 2024
Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)
Stefano Aliberti, Felix C Ringshausen, Raja Dhar, et al.
The Lancet. Respiratory Medicine
|
November 10, 2021
Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial
Jozefien Declercq, Karel F A Van Damme, Elisabeth De Leeuw, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 71) with videos related to
Sort By:
Page
of 8
ERJ Open Research
|
April 13, 2022
Prospective longitudinal evaluation of hospitalised COVID-19 survivors 3 and 12 months after discharge
Natalie Lorent, Yannick Vande Weygaerde, Eveline Claeys, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
April 2, 2026
Effects of Elexacaftor/Tezacaftor/Ivacaftor on cough frequency, physical activity patterns, and sleep quality in adolescents and adults with cystic fibrosis
Eva Van Braeckel, Andrew T Braun, Nicholas J Simmonds, et al.
Respiratory Research
|
August 9, 2022
Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
Elisabeth De Leeuw, Karel F A Van Damme, Jozefien Declercq, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
March 20, 2026
Determinants of early Elexacaftor-Tezacaftor-Ivacaftor use in adults with cystic fibrosis and preserved lung function: insights from a European multicenter survey
Andrea Gramegna, Carlo Magnoni, Chiara Premuda, et al.
Cell Reports. Medicine
|
December 2, 2022
Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment
Cedric Bosteels, Karel F A Van Damme, Elisabeth De Leeuw, et al.
ERJ Open Research
|
July 14, 2026
The association between chronic rhinosinusitis, bronchiectasis and type 2 inflammation: an EMBARC registry analysis
Michal Shteinberg, Charles S Haworth, Jennifer Pollock, et al.
The Journal of Allergy and Clinical Immunology
|
February 24, 2024
Bronchiectasis and asthma: Data from the European Bronchiectasis Registry (EMBARC)
Eva Polverino, Katerina Dimakou, Letizia Traversi, et al.
Thorax
|
March 23, 2025
Use of inhaled corticosteroids in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)
Jennifer Pollock, Eva Polverino, Raja Dhar, et al.
The European Respiratory Journal
|
April 12, 2024
Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)
Stefano Aliberti, Felix C Ringshausen, Raja Dhar, et al.
The Lancet. Respiratory Medicine
|
November 10, 2021
Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial
Jozefien Declercq, Karel F A Van Damme, Elisabeth De Leeuw, et al.
Page
of 8